Clinical Patterns of Melanoma in Asians: 11-Year Experience in a Tertiary Referral Center
- PMID: 26808749
- DOI: 10.1097/SAP.0000000000000731
Clinical Patterns of Melanoma in Asians: 11-Year Experience in a Tertiary Referral Center
Abstract
Background: Malignant melanoma is a relatively common malignancy in the West, but has a significantly lower incidence in Asians. Stark contrast in clinicopathological characteristics and prognosis has been observed between the 2 populations, yet data are limited. Here, we evaluate 106 Asian patients from a tertiary referral center in Hong Kong during an 11-year period. The purpose of this study was to collectively review all types of melanomas to analyze the clinicopathological characteristics of this poorly understood condition in an Asian population.
Methods: A total of 106 patients diagnosed with malignant melanoma from 2002 to 2012 were retrospectively reviewed. Demographics, clinical presentations, pathological subtypes, treatments, and survival outcomes were evaluated.
Results: Cutaneous melanomas dominated with 46 (43.4%) cases, followed by mucosal (39.6%), ocular (9.4%), and melanomas of unknown primary (7.5%); 43.3% patients presented in stage I, 36.7% in stage II, 18.9% in stage III, and 1.1% in stage IV. Acral lentiginous melanoma was the commonest subtype of cutaneous melanomas (60.9%). When types of melanomas were reviewed collectively, the median overall survival, disease-specific survival, and recurrence-free survival were 37, 45, and 48 months, respectively. Cutaneous melanoma had the best median overall survival of 59 months, followed by ocular melanoma (58 months), mucosal melanoma (18 months), and melanoma of unknown primary (2 months). Similar patterns were observed for disease-specific survival and recurrence-free survival.
Conclusions: Melanoma among Asians remains poorly understood. There is a clear distinction in the clinical patterns between Asians and whites and the difference is not solely accounted for by the lower incidence of cutaneous melanoma. Certain subtypes, such as mucosal melanoma and is acral lentiginous melanoma, seemed to have disproportionately high incidences. Further studies are warranted to elucidate these observations. The poor survival outcomes reflected the need for better awareness and understanding of the condition by both the general public and the physicians.
Similar articles
-
Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.Melanoma Res. 2023 Aug 1;33(4):326-331. doi: 10.1097/CMR.0000000000000901. Epub 2023 May 18. Melanoma Res. 2023. PMID: 37199704
-
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.BMC Cancer. 2011 Feb 25;11:85. doi: 10.1186/1471-2407-11-85. BMC Cancer. 2011. PMID: 21349197 Free PMC article.
-
Rare presentations of primary melanoma and special populations: a systematic review.Am J Clin Oncol. 2014 Dec;37(6):635-41. doi: 10.1097/COC.0b013e3182868e82. Am J Clin Oncol. 2014. PMID: 23563206 Free PMC article. Review.
-
Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese.Clin Exp Dermatol. 2004 Nov;29(6):600-4. doi: 10.1111/j.1365-2230.2004.01644.x. Clin Exp Dermatol. 2004. PMID: 15550131
-
Primary mucosal melanoma.J Am Acad Dermatol. 2007 May;56(5):828-34. doi: 10.1016/j.jaad.2006.06.017. Epub 2007 Mar 8. J Am Acad Dermatol. 2007. PMID: 17349716 Review.
Cited by
-
Local recurrence and metastasis in patients with malignant melanomas after surgery: A single-center analysis of 202 patients in South Korea.PLoS One. 2019 Mar 7;14(3):e0213475. doi: 10.1371/journal.pone.0213475. eCollection 2019. PLoS One. 2019. PMID: 30845184 Free PMC article.
-
Advances in the Application of Nanomaterials to the Treatment of Melanoma.Pharmaceutics. 2022 Sep 30;14(10):2090. doi: 10.3390/pharmaceutics14102090. Pharmaceutics. 2022. PMID: 36297527 Free PMC article. Review.
-
Endoscopic ultrasound features of rectal melanoma: A case report and review of literature.World J Clin Cases. 2024 Jun 6;12(16):2862-2868. doi: 10.12998/wjcc.v12.i16.2862. World J Clin Cases. 2024. PMID: 38899292 Free PMC article.
-
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial.J Clin Oncol. 2019 Nov 10;37(32):2987-2999. doi: 10.1200/JCO.19.00210. Epub 2019 Aug 12. J Clin Oncol. 2019. PMID: 31403867 Free PMC article. Clinical Trial.
-
Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.Int J Environ Res Public Health. 2021 Jun 8;18(12):6194. doi: 10.3390/ijerph18126194. Int J Environ Res Public Health. 2021. PMID: 34201096 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical